Alnylam Pharmaceuticals (ALNY) Assets (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Assets data on file, last reported at $5.6 billion in Q2 2026.

• Quarterly Assets rose 21.74% year-over-year to $5.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.6 billion (up 21.74% YoY) and the FY2025 annual result came in at $5.0 billion, up 17.13% from the prior year.
• Assets improved to $5.6 billion in Q2 2026, from $5.1 billion in the prior quarter.
• In the past five years, Assets ranged from a high of $5.6 billion in Q2 2026 to a low of $3.3 billion in Q2 2022.
• A 5-year average of $4.1 billion and a median of $3.9 billion in 2023 frame the typical range for Assets.
• Annual changes were most pronounced in 2022 — Assets dropped 5.1% — and 2026, when it climbed 21.74%.
• Tracing ALNY's Assets over 5 years: stood at $3.5 billion in 2022, then climbed by 7.99% to $3.8 billion in 2023, then grew by 10.71% to $4.2 billion in 2024, then gained by 17.13% to $5.0 billion in 2025, then gained by 11.93% to $5.6 billion in 2026.
• The last three Assets figures came in at $5.6 billion (Q2 2026), $5.1 billion (Q1 2026), and $5.0 billion (Q4 2025), per Business Quant data.